Olivier Harismendy

19PUBLICATIONS
96CO-AUTHORS
Predictive and prognostic markersMolecular targetsCancer diagnosisEpigenetics (incl. genome methylation and epigenomics)Proteomics and intermolecular interactions (excl. medical proteomics)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (19)

|Aug 26, 2026
Molecular Response Assessment From Circulating Tumor DNA in Patients With Ovarian Cancer Treated With the WEE1 Inhibitor Azenosertib.

|Apr 15, 2025
Azenosertib Is a Potent and Selective WEE1 Kinase Inhibitor with Broad Antitumor Activity Across a Range of Solid Tumors.

Jianhui Ma, Wen Liu, Jiali Li

|Jan 14, 2025
The Selective WEE1 Inhibitor Azenosertib Shows Synergistic Antitumor Activity with KRASG12C Inhibitors in Preclinical Models.

Nathan M Jameson, Daehwan Kim, Catherine Lee

|Sep 18, 2023
Integrated Molecular Characterization of Intraductal Papillary Mucinous Neoplasms: An NCI Cancer Moonshot Precancer Atlas Pilot Project.

Alexander Semaan, Vincent Bernard, Justin Wong

|Dec 27, 2022
Accurate genome-wide genotyping from archival tissue to explore the contribution of common genetic variants to pre-cancer outcomes.

Daniela Nachmanson, Meghana Pagadala, Joseph Steward

|Oct 04, 2022
A Randomized Multi-institutional Phase II Trial of Everolimus as Adjuvant Therapy in Patients with Locally Advanced Squamous Cell Cancer of the Head and Neck.

Cherie-Ann O Nathan, D Neil Hayes, Theodore Karrison

Pageof 4

Frequent Collaborators

3 joint publications

Jianhui Ma

2 joint publications

Mark R Lackner

2 joint publications

Daehwan Kim

2 joint publications

Adam M Burgoyne